CLSD Stock Summary

• Clearside Biomedical Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 7.77% of US listed stocks.
• CLSD's price/sales ratio is 405.92; that's higher than the P/S ratio of 99.3% of US stocks.
• Revenue growth over the past 12 months for Clearside Biomedical Inc comes in at -42.86%, a number that bests only 4.2% of the US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to Clearside Biomedical Inc, a group of peers worth examining would be QURE, SCYX, CRNX, RETA, and ARQL.
• Visit CLSD's SEC page to see the company's official filings. To visit the company's web site, go to www.clearsidebio.com.